Bangalore – OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter (Q4FY26) and full year ended March 31, 2026.
Financial Highlights (In ₹ million)
| Particulars | Q4FY26 | Q3FY26 | QoQ | FY26 | FY25 | YoY |
| Revenues | 4,282 | 2,903 | 47% | 14,216 | 14,449 | (2%) |
| EBITDA | 919 | 173 | 5x+ | 3,042 | 4,665 | (35%) |
| EBITDA % | 21% | 6% | 1550bps | 21% | 32% | (1089bps) |
| Adjusted PAT1 | 390 | (472) | Loss to profit | 739 | 2,314 | (68%) |
| Adjusted EPS1 | 3.4 | (4.1) | Loss to profit | 6.5 | 21.0 | (69%) |
Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “We saw a strong recovery in Q4 driven by broad-based business performance. The quarter was marked by successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses. With the recent back-to-back semaglutide approvals in Canada and continued expansion of our biologics pipeline, we are well positioned to sustain growth momentum into FY27.”
